232 related articles for article (PubMed ID: 30366412)
21. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Emadi A; Jun SA; Tsukamoto T; Fathi AT; Minden MD; Dang CV
Exp Hematol; 2014 Apr; 42(4):247-51. PubMed ID: 24333121
[TBL] [Abstract][Full Text] [Related]
22. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
23. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra KC; DiNardo CD
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
[TBL] [Abstract][Full Text] [Related]
24. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
Lim INX; Nagree MS; Xie SZ
Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
[TBL] [Abstract][Full Text] [Related]
25. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features.
Pabst T; Kortz L; Fiedler GM; Ceglarek U; Idle JR; Beyoğlu D
BBA Clin; 2017 Jun; 7():105-114. PubMed ID: 28331812
[TBL] [Abstract][Full Text] [Related]
26. [Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Geng Z; Wang HX; Wang J; Xu YL; Li TJ; Zhou JF; Li CR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1307-11. PubMed ID: 23257422
[TBL] [Abstract][Full Text] [Related]
27. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
28. [IDH1 Gene Mutation and Its Clinical Significance in patients with Acute Myeloid Leukemia].
Wei JF; Qiu HY; Chen GH; Wang Y; Chen Z; Liu HJ; Mao JP; Jia T; Xue LG; Cai ZM; Zhu YX; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1252-7. PubMed ID: 26524018
[TBL] [Abstract][Full Text] [Related]
29. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
Izquierdo-Garcia JL; Viswanath P; Eriksson P; Cai L; Radoul M; Chaumeil MM; Blough M; Luchman HA; Weiss S; Cairncross JG; Phillips JJ; Pieper RO; Ronen SM
Cancer Res; 2015 Aug; 75(15):2999-3009. PubMed ID: 26045167
[TBL] [Abstract][Full Text] [Related]
30. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
[TBL] [Abstract][Full Text] [Related]
31. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
32. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
[TBL] [Abstract][Full Text] [Related]
33. Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF; Xu WR
Clin Biochem; 2011 Jul; 44(10-11):779-83. PubMed ID: 21539821
[TBL] [Abstract][Full Text] [Related]
34. Mutation of IDH1 aggravates the fatty acid‑induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain.
Li S; Sun C; Gu Y; Gao X; Zhao Y; Yuan Y; Zhang F; Hu P; Liang W; Cao K; Zhang J; Wang Z; Ye J
Mol Med Rep; 2019 Apr; 19(4):2509-2518. PubMed ID: 30720071
[TBL] [Abstract][Full Text] [Related]
35. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243
[TBL] [Abstract][Full Text] [Related]
36. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
37. A Zebrafish Model for Evaluating the Function of Human Leukemic Gene IDH1 and Its Mutation.
Ma ACH; Shi X; He BL; Guo Y; Leung AYH
Methods Mol Biol; 2017; 1633():193-218. PubMed ID: 28735489
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
39. Variation in Lipid Species Profiles among Leukemic Cells Significantly Impacts Their Sensitivity to the Drug Targeting of Lipid Metabolism and the Prognosis of AML Patients.
Lo Presti C; Yamaryo-Botté Y; Mondet J; Berthier S; Nutiu D; Botté C; Mossuz P
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983080
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
